We’re Serious About Innovative Cancer Treatments

At ESSA, we’re focused on the development of small molecule drugs for the treatment of cancer, with an initial focus on advanced prostate cancer. ESSA is developing drugs that selectively block transcription at the N-terminal domain of the androgen receptor (AR), a novel target for next-generation hormone therapy. Our lead product candidate, EPI-506, is currently being studied in patients with advanced prostate cancer, the most commonly diagnosed cancer among men and a leading cause of male cancer death worldwide.